Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$83.78 USD

83.78
45,084

+1.45 (1.76%)

Updated Jun 28, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LGND or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

by Zacks Equity Research

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Bausch Health (BHC) Secures $600M Financing Facility, Stock Up

by Zacks Equity Research

Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.

Novartis (NVS) Entresto Patent Faces Setback, Stock Down

by Zacks Equity Research

Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.

Factors That Make Universal Health (UHS) an Attractive Bet Now

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

by Zacks Equity Research

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug

by Zacks Equity Research

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus

by Zacks Equity Research

Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.

Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug

by Zacks Equity Research

Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.

Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.

Shrabana Mukherjee headshot

3 Stocks to Buy on New Analyst Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as Ligand (LGND), Ambac (AMBC) and Exponent (EXPO) indicates the potential for significant price appreciation in the near term.

Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study

by Zacks Equity Research

Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.

Benjamin Rains headshot

Find Stocks to Buy in July that are Gaining More Attention on Wall Street

by Benjamin Rains

Here is how to use our new analyst coverage screen to help investors find stocks to buy in July and for the second half of 2023.

FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study

by Zacks Equity Research

FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.

Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval

by Zacks Equity Research

Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.

Intercept (ICPT) to Restructure Operations, Cut Workforce

by Zacks Equity Research

Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.

Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

Gilead Sciences (GILD) Announces Positive HDV Treatment Data

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.

Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee

by Zacks Equity Research

Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.

Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA

by Zacks Equity Research

Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

LGND vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review

by Zacks Equity Research

bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.